Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

NCT05150652 is registered in ClinicalTrials.gov with Irada Ibrahim-zada as lead sponsor.

NCT NCT05150652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05150652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
Lead sponsor
Irada Ibrahim-zada
Phase
Phase 2
Overall status
Completed
Start date
February 18, 2022
Completion date
June 10, 2026
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast carcinoma, her2-negative breast cancer, node-negative breast cancer